Otsuka Pharma To Invest Big: $1.1 Billion Deal For Jnana Therapeutics Aims To Revolutionize Treatment

Japan’s Otsuka Pharmaceutical (4578.T) announced on Thursday that it has reached an agreement to acquire Jnana Therapeutics for over $1 billion, aiming to bolster its drug pipeline and research efforts in the Boston region. This move aligns Otsuka with domestic competitors such as Ono Pharma (4528.T), Takeda Pharmaceutical (4502.T), and Astellas Pharma (4503.T), all of whom are pursuing significant international acquisitions to enhance their drug portfolios.

Under the agreement, Otsuka will pay $800 million to Jnana’s shareholders, with an additional $325 million contingent upon meeting development and regulatory milestones. The transaction is slated for completion by the third quarter of this year. Jnana Therapeutics, a clinical-stage biotech firm, specializes in therapies for rare diseases and immune disorders, with its leading candidate JNT-517 targeting phenylketonuria (PKU), a rare genetic metabolic condition.

Otsuka, known for its psychiatric medications like the antipsychotic Abilify and cancer therapies, also has a consumer products division that includes the Pocari Sweat electrolyte drink and Calorie Mate energy bar. The company is also recognized for developing Abilify MyCite, the world’s first FDA-approved digitally connected drug.